VM 206

Drug Profile

VM 206

Alternative Names: VM-206; VM-206RY; VM206DNA

Latest Information Update: 08 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViroMed Co Ltd
  • Developer Reyon Pharmaceutical; ViroMed
  • Class Cancer vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 22 Oct 2013 Reyon Pharmaceutical completes a phase I trial in Breast cancer in South Korea (NCT01895491)
  • 03 Oct 2011 RecipharmCobra Biologics is now called Cobra Biologics
  • 31 Mar 2011 Phase-I clinical trials in Breast cancer (second-line therapy or greater) in South Korea (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top